Cryo-Cell International (STU:ZCY) Research & Development: €0.30 Mil (TTM As of Feb. 2026)


STU:ZCY Cryo-Cell International Inc STU:ZCY
58 GF Score
Price €2.36
GF Value €4.06
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cryo-Cell International Research & Development?

Cryo-Cell International STU:ZCY -23.87% 58 Research & Development is €0.30 Mil as of Feb. 2026. GuruFocus rates STU:ZCY with a GF Score™ of 58/100 and a GF Value™ of €4.06 (Possible Value Trap). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Cryo-Cell International's Research & Development for the three months ended in Feb. 2026 was €0.06 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Feb. 2026 was €0.30 Mil.

Cryo-Cell International  (STU:ZCY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cryo-Cell International Research & Development Related Terms

Cryo-Cell International Research & Development Historical Data

* Premium members only.

The historical data trend for Cryo-Cell International's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryo-Cell International Research & Development Chart

Cryo-Cell International Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.38 1.08 1.17 0.33

Cryo-Cell International Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.12 0.05 0.07 0.06
STU:ZCY
58GF Score
Cryo-Cell International Inc STU:ZCY
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cryo-Cell International Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.30 Mil mean?
Cryo-Cell International (STU:ZCY) has a Research & Development of €0.30 Mil as of Feb. 2026. Research and development expense is the total cost for research and development activities. View historical data on Cryo-Cell International and its competitors.
Is Cryo-Cell International's Research & Development too high?
Cryo-Cell International's current Research & Development is €0.30 Mil. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Research & Development compare to CCM and CDIX?
Cryo-Cell International's Research & Development of €0.30 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cryo-Cell International and its competitors. Cryo-Cell International's current Research & Development is €0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (STU:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €4.06, compared to a current price of €2.36 — trading 41.9% below its estimated fair value. The current Research & Development is €0.30 Mil. Cryo-Cell International's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cryo-Cell International (STU:ZCY), the current Research & Development is €0.30 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryo-Cell International (STU:ZCY) Overvalued in 2026?

Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued. The current stock price of €2.36 is trading 41.9% below its estimated GF Value™ of €4.06. GuruFocus considers Cryo-Cell International to be Possible Value Trap.

Key valuation signals for STU:ZCY:

  • Research & Development: €0.30 Mil
  • GF Value™: €4.06 vs. price of €2.36 (41.9% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the STU:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cryo-Cell International Business Description

Other Exchanges CCEL:USAZCY:Germany
Address 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score

Get the complete analysis for STU:ZCY

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.36
Price
€4.06
GF Value